Search

Your search keyword '"Eyre, T."' showing total 198 results

Search Constraints

Start Over You searched for: Author "Eyre, T." Remove constraint Author: "Eyre, T."
198 results on '"Eyre, T."'

Search Results

2. Dominance and rarity in tree communities across the globe: Patterns, predictors and threats

3. Positive feedbacks and alternative stable states in forest leaf types

7. The global biogeography of tree leaf form and habit

8. Integrated global assessment of the natural forest carbon potential

9. Evenness mediates the global relationship between forest productivity and richness

12. PIRTOBRUTINIB IN COVALENT BTK‐INHIBITOR PRE‐TREATED MANTLE CELL LYMPHOMA: UPDATED RESULTS, SUBGROUP ANALYSIS FROM BRUIN WITH >3 YEARS FOLLOW‐UP FROM START OF ENROLLMENT.

13. P1141: IBRUTINIB AND RITUXIMAB AS FIRST LINE THERAPY FOR MANTLE CELL LYMPHOMA: A MULTICENTRE, REAL-WORLD UK STUDY

14. P671: TREATMENT SEQUENCES AND OUTCOMES OF PATIENTS WITH CLL TREATED WITH TARGETED AGENTS IN REAL-WORLD SETTINGS

15. P1100: BRUIN MCL-321: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB VS INVESTIGATOR CHOICE OF BTK INHIBITOR IN PATIENTS WITH PREVIOUSLY TREATED, BTK INHIBITOR NAÏVE MCL (TRIAL IN PROGRESS)

16. S147: PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVERSIBLE) BTK INHIBITOR IN PREVIOUSLY TREATED CLL/SLL: UPDATED RESULTS FROM THE PHASE 1/2 BRUIN STUDY

18. P1101: PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVERSIBLE) BTK INHIBITOR IN PREVIOUSLY TREATED MANTLE CELL LYMPHOMA: UPDATED RESULTS FROM THE PHASE 1/2 BRUIN STUDY

19. PB1863: BRUIN CLL-322: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF FIXED DURATION PIRTOBRUTINIB+VENETOCLAX AND RITUXIMAB VS VENETOCLAX AND RITUXIMAB IN PREVIOUSLY TREATED CLL/SLL (TRIAL IN PROGRESS)

20. Co-limitation towards lower latitudes shapes global forest diversity gradients

23. Diffuse large B cell lymphoma (DLBCL) in patients older than 65 years: analysis of 3 year Real World data of practice patterns and outcomes in England

25. GENOMIC EVOLUTION AND RESISTANCE TO PIRTOBRUTINIB IN COVALENT BTK‐INHIBITOR PRE‐TREATED CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS: RESULTS FROM THE PHASE I/II BRUIN STUDY.

26. PIRTOBRUTINIB (LOXO‐305), A NEXT GENERATION HIGHLY SELECTIVE NON‐COVALENT BTK INHIBITOR IN PREVIOUSLY TREATED RICHTER TRANSFORMATION: RESULTS FROM THE PHASE 1/2 BRUIN STUDY

27. Ensembl 2008

31. Ensembl 2008

32. Climatic controls of decomposition drive the global biogeography of forest-tree symbioses

33. Author Correction: Climatic controls of decomposition drive the global biogeography of forest-tree symbioses

35. Climatic controls of decomposition drive the global biogeography of forest-tree symbioses

36. A phase 1 study to assess the safety, tolerability, and pharmacokinetics of CXD101 in patients with advanced cancer

38. IBRUTINIB FOR THE TREATMENT OF BING-NEEL SYNDROME: A RETROSPECTIVE, MULTICENTER STUDY

39. NCRI PETREA TRIAL: A PHASE 3 EVALUATION OF PET-GUIDED, RESPONSE-ADAPTED THERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED, ADVANCED-STAGE, HIGH-TUMOUR-BURDEN FOLLICULAR LYMPHOMA

40. PF381 FACTORS IMPACTING TREATMENT SELECTION IN TREATMENT-NAÏVE PATIENTS WITH CLL: A MULTICENTER STUDY

41. Impact of intended and relative dose intensity of R‐CHOP in a large, consecutive cohort of elderly diffuse large B‐cell lymphoma patients treated with curative intent: no difference in cumulative incidence of relapse comparing patients by age

43. The impact of CHOP versus bendamustine on bone mineral density in patients with follicular lymphoma enrolled in the GALLIUM study.

45. Enumerating a continental-scale threat: How many feral cats are in Australia?

47. Enumerating a continental-scale threat: How many feral cats are in Australia?

48. Ensembl 2008

49. Enumerating a continental-scale threat: How many feral cats are in Australia?

50. Ensembl 2008

Catalog

Books, media, physical & digital resources